TABLE 2

Growth and Medical Outcomes

DarbeEpoPlacebo
Corrected age at follow-up (mo)20.5 ± 1.121.2 ± 2.020.6 ± 1.9
 Median20.021.020.0
 Interquartile range20.0–21.020.0–22.019.5–21.0
Corrected wt at follow-up (kg)11.2 ± 3.311.1 ± 2.111.0 ± 1.4
 Median10.910.811.1
 Interquartile range9.4–11.39.6–12.010.0–12.0
Less than 10th percentile for wt, N (%)7 (25.9)6 (20.7)5 (20.8)
Recumbent length at follow-up (cm)79.9 ± 5.683.3 ± 4.083.4 ± 4.1
 Median80.584.082.4
 Interquartile range77.5–84.481.2–86.580.5–85.7
Head circumference at follow-up (cm)46.7 ± 2.247.8 ± 2.247.1 ± 1.5
 Median46.647.547.0
 Interquartile range45.8–48.046.5–49.346.0–48.4
Less than 10th percentile for head circumference, N (%)3 (11.1)3 (10.3)5 (20.8)
ROP
 All stages10 (37.0)8 (27.6)8 (33.3)
 Stage ≥3, regressed, N (%)0 (0)1 (3.5)2 (8.3)
 Stage ≥3, requiring intervention, N (%)2 (7.4)0 (0)1 (4.2)
Intraventricular hemorrhage grade ≥3, N (%)2 (7.4)2 (6.9)5 (20.8)
Necrotizing enterocolitis, N (%)0 (0)1 (3.5)1 (4.2)
Bronchopulmonary dysplasia, N (%)17 (63.0)20 (69.0)14 (58.3)
Rehospitalized, N (%)13 (48.2)11 (37.9)9 (37.5)
Average readmissions, N (%)2.0 ± 1.51.4 ± 0.71.8 ± 1.2
 Median1.01.01.0
 Interquartile range1.0–2.21.0–2.01.0–3.0
Surgically treated after initial discharge, N (%)6 (22.2)8 (27.6)6 (25)
ROP surgery, N (%)0 (0)1 (3.5)0 (0)
Shunt for hydrocephalus, N (%)0 (0)1 (3.5)0 (0)
Patent ductus arteriosus ligation, N (%)0 (0)1 (3.5)0 (0)
Other, N (%)1 (3.7)3 (10.3)2 (8.3)
  • All differences are statistically insignificant.